Group items tagged

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

Market Overview: Skin substitutes are natural, synthetic or biosynthetic materials, used to cover large wounds to restore at least some of the functions of the skin. Skin substitutes provides temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound. Skin substitutes provide a permanent solution and are used in the treatment of conditions like burns, trauma wounds, diabetes or venous ulcers, where skin grafts may not be possible. Market Dynamics: Rising chronic skin diseases is expected to drive the skin substitutes market. For instance, according to the global burden of disease study 2013, Skin conditions contributed around 1.79% to the global disease burden. According to the World Health Organization, about 132,000 melanoma skin cancers occur each year worldwide. Thus, the rising chronic diseases is increasing the demand for skin substitutes in the forecast period. Rising prevalence of diabetes is expected to boost the market. This is owing to the risk of developing a diabetic foot ulcer over the period of time in diabetic patients. For instance, WHO has reported that the incidence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is anticipated to rise from 171 million in 2000 to 366 million in 2030. Thus, as a consequence, the prevalence of diabetes related complications are expected to increase over the forecast period. There are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection. Market Segmentation: Rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the skin substitutes market. For instance, the American Society of Plastic Surgeons in 2012, reported that

Cancer Research UK has announced a £56m research network to transform the UK into a global hub for radiotherapy study. By leveraging the use of the latest techniques, such as FLASH radiotherapy and artificial intelligence (AI), the network aims to accelerate the development of advanced radiotherapy.

Researchers from UCL and the National Center for Social Research have reported that, between 1994 and 2019, the number of adults with diagnosed diabetes tripled.

Researchers at Heriot-Watt University in Edinburgh, Scotland are developing smart sensors which can monitor the healing progress of a wound, eliminating the need to look underneath a bandage.

Apple has joined forces with Eli Lilly and Evidation Health on a new feasibility study to detect evidence of brain decline with data from personal digital devices. The research has revealed that these devices may help in the identification of mild cognitive impairment (MCI) and Alzheimer's disease dementia.

Researchers at Stanford University in the US have developed new sensors that can be adhered to the skin for wireless monitoring of health. The sensors are designed to identify the physiological signals that the skin emanates, such as pulse. These readings will be wirelessly transmitted to a receiver clipped onto clothing. The sensor and receiver system has been named BodyNet.

Researchers from the Max Planck Institute for Biology of Ageing in Germany and the Leiden University Medical Center (LUMC) in the Netherlands have discovered new blood biomarkers that could indicate a mortality risk in elderly people.

Seven new 'data hubs' are set to revolutionise medical research across Britain, making the medical histories of millions of NHS patients available to doctors, scientists and academics.

Companion animals are domesticated or domestic-bred animals whose physical, emotional, behavioral and social needs can be readily met as companions in the home or a close daily relationship with humans. Companion animal health market mainly comprises of medicines, medicinal feed additives, and vaccines and caters to both foods producing and companion animals. China Companion Animal Health Market was worth US$ XX Million in 2019 and is expected to reach US$ XX Million by 2026, at a CAGR of XX% during the forecast period 2019-2026. Download Free Sample Report: https://www.datamintelligence.com/download-sample/china-companion-animal-health-market View Full Report Sample: https://www.datamintelligence.com/research-report/china-companion-animal-health-market

Chronic Immune Thrombocytopenia (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes, causing a decrease in platelet production. The global chronic immune thrombocytopenia market size was worth $ XX billion in 2019 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026). View Full Report Sample: https://www.datamintelligence.com/research-report/chronic-immune-thrombocytopenia-market Download free Report Sample: https://www.datamintelligence.com/download-sample/chronic-immune-thrombocytopenia-market

Unlock efficiency in clinical research with EDC. Streamline data, enhance accuracy. Elevate your trials today for a future of impactful discoveries!

ClinViiglant is a leading clinical trial solutions provider and provides solutions in clinical trial services & Clinical Digital Solutions Contact Now

The majority of women who undergo surgery for suspected ovarian cancer do not actually have the disease, but these unnecessary surgeries could soon be reduced thanks to a novel blood test developed by a Swedish research team.

The global biopharmaceuticals market is set to exhibit a CAGR of 7.83% during 2019-2026 and is estimated to reach a market value of US $ XX billion by 2026. Biopharmaceuticals are large and complex molecular drugs that are mainly obtained from proteins and nucleic acids of living organisms such as microorganisms and animal cells also known as transgenic organisms. These drugs are obtained using biotechnology and have high-therapeutic value. Biopharmaceuticals are also known as biologics and biotech drugs and are usually administered by intravenous, subcutaneous, or intramuscular injections and are more efficient than the conventional small molecule drugs. Biopharmaceuticals are an alternative to the previously less effective and sometimes unsafe treatments and offer several benefits. Biopharmaceuticals benefits include highly effective and potent action, fewer side effects, can be tailored according to specific medical requirements of patients and they hold the potential to actually cure diseases at the root level. Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade and have changed the treatment of several chronic diseases, such as diabetes and cardiovascular diseases. Download free Report Sample: https://www.datamintelligence.com/download-sample/biopharmaceuticals-market View Full Report Sample: https://www.datamintelligence.com/research-report/biopharmaceuticals-market

MedRhythms, a US-based digital therapeutics company, has launched its five-site randomised controlled trial (RCT) at rehabilitation hospitals and research centres to examine a post-stroke walking rehabilitation device.

Carpal Tunnel Syndrome can be incredibly painful. CBD is known as help for all types of bodily pains, and research shows that it's been effective at dealing with various medical conditions. Discover how CBD Oil with Terpenes helps patients recover from their post carpal tunnel surgery. Read the frequently asked questions about it here in the blog.

Dr. P Jagannath India is well known for his research work in the fields of cancer treatment and liver cancer treatment in India.